Figure 1.
Overall analysis of trials evaluating the effect of antitumor necrosis factor (including adalimumab and certolizumab) for induction of remission at week 4.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.